Patents by Inventor Neil W. Gibson

Neil W. Gibson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeting MicroRNAs for Metabolic Disorders
    Publication number: 20190153444
    Abstract: Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.
    Type: Application
    Filed: September 25, 2018
    Publication date: May 23, 2019
    Applicant: Regulus Therapeutics Inc.
    Inventors: Balkrishen Bhat, Neil W. Gibson, Diedre MacKenna, Brandee Wagner, David P. Bartel
  • Targeting microRNAs for metabolic disorders
    Patent number: 10138484
    Abstract: Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: November 27, 2018
    Assignee: Regulus Therapeutics Inc.
    Inventors: Balkrishen Bhat, Neil W. Gibson, Diedre MacKenna, Brandee Wagner, David P. Bartel
  • TARGETING MICRORNAS FOR METABOLIC DISORDERS
    Publication number: 20180171334
    Abstract: Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.
    Type: Application
    Filed: October 5, 2017
    Publication date: June 21, 2018
    Applicant: Regulus Therapeutics Inc.
    Inventors: Balkrishen Bhat, Neil W. Gibson, Diedre MacKenna, Brandee Wagner, David P. Bartel
  • Targeting microRNAs for metabolic disorders
    Patent number: 9862950
    Abstract: Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 9, 2018
    Assignee: Regulus Therapeutics Inc.
    Inventors: Balkrishen Bhat, Neil W. Gibson, Diedre MacKenna, Brandee Wagner, David P. Bartel
  • TARGETING MICRORNAS FOR METABOLIC DISORDERS
    Publication number: 20170067051
    Abstract: Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 9, 2017
    Applicant: Regulus Therapeutics Inc.
    Inventors: Balkrishen Bhat, Neil W. Gibson, Diedre MacKenna, Brandee Wagner, David P. Bartel
  • Targeting microRNAs for metabolic disorders
    Patent number: 9487783
    Abstract: Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: November 8, 2016
    Assignee: Regulus Therapeutics Inc.
    Inventors: Balkrishen Bhat, Neil W. Gibson, Diedre MacKenna, Brandee Wagner, David P. Bartel
  • TARGETING MICRORNAS FOR METABOLIC DISORDERS
    Publication number: 20160046940
    Abstract: Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.
    Type: Application
    Filed: August 6, 2015
    Publication date: February 18, 2016
    Inventors: Balkrishen Bhat, Neil W. Gibson, Diedre MacKenna, Brandee Wagner, David P. Bartel